COST ANALYSIS FOR THE TREATMENT OF SEVERE UNCONTROLLED BRONCHIAL ASTHMA IN THE RUSSIAN FEDERATION

OBJECTIVES Update of cost analysis for treatment of severe uncontrolled bronchial asthma in the Russian Federation.

METHODS We have identified the direct costs associated with the treatment of uncontrolled bronchial asthma. Direct costs included the cost of pharmacotherapy of bronchial asthma, the treatment of bronchial asthma in remission, hospitalization of patients with inpatient and emergency medical care, as well as the correction of side effects from the used pharmacotherapy. The exchange rate was set at $ 1 = 66 RUB.

RESULTS The cost of pharmacotherapy, in according to the international recommendations of GINA, per patient was $ 4 431. The cost of treating one patient in remission was $ 1 041. Expenses for compensation of exacerbations, including those requiring medical care in a hospital, were $ 740 per patient. The side effect compensation was $ 33. Thus, the cumulative direct costs associated with the treatment of uncontrolled severe bronchial asthma in adults were $ 6 243 per patient for one year. Recalculation of costs for the entire population of patients with asthma in Russia, which amounts to 1 515 296 people in 2016 (10% of them occur in patients with severe bronchial asthma), revealed that the total cost of treating all patients with uncontrolled severe bronchial asthma in Russia is $ 9 430 918 759.

CONCLUSIONS The results of cost analysis for the treatment of bronchial asthma in adults in the Russian Federation per patient and for the entire population were updated.